Smoking cessation treatment for COPD smokers: the role of pharmacological interventions

https://doi.org/10.4081/monaldi.2013.106

Authors

  • C.A. Jiménez-Ruiz | victorina@ctv.es Unidad Especializada en Tabaquismo, Madrid, Spain.
  • K.O. Fagerström Fagerström Consulting. Kagerod, Sweden.

Abstract

Because stopping smoking is such a pressing necessity for COPD smokers physicians should use smoking cessation treatments aggressively. For optimal efficacy smoking cessation in COPD smokers should combine behavioral and pharmacological treatments. Three types of pharmacological treatments are proven to be safe and effective: Nicotine Replacement Therapy (NRT), Bupropion and Varenicline. Use of NRT, bupropion or varenicline, single or in combination, at standard doses or at high doses, for 8-12 weeks or for more than 6-12 months have proven to help these patients to quit. For optimizing efficacy these medications can also be introduced some weeks before actual quitting. In COPD smoking patients that are not interested in stopping completely or abruptly these medications can be used to aid cessation in a more gradual way. Pharmacotherapy to aid cessation in COPD smokers have proven to be highly cost effective.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Downloads

Published
2015-11-26
Info
Issue
Section
Reviews
Keywords:
Smoking, Pharmacological treatment, Varenicline, Bupropion, Nicotine replacement therapy, High doses of nicotine replacement therapy, COPD smokers
Statistics
  • Abstract views: 1585

  • PDF: 852
How to Cite
Jiménez-Ruiz, C.A., and K.O. Fagerström. 2015. “Smoking Cessation Treatment for COPD Smokers: The Role of Pharmacological Interventions”. Monaldi Archives for Chest Disease 79 (1). https://doi.org/10.4081/monaldi.2013.106.

Most read articles by the same author(s)